WebDisclosure WebDisclosure
Basculer en Français
11223 Companies
248904 Keywords
176714 Articles
134728 Press releases
Headlines Articles Press releases RedHill Biopharma Ltd. Remove
  1. Home
  2. Companies
  3. RedHill Biopharma Ltd.
WebDisclosure
Basculer en Français
Headlines Articles Press releases

News

  • BRIEF

    published on 06/03/2026 at 18:15, 4 months 20 days ago

    RedHill Biopharma Explores Opaganib for Ebola Virus Amid Outbreak

    Clinical Trials Infectious Disease Ebola Virus Opaganib RedHill Biopharma
  • BRIEF

    published on 06/03/2026 at 18:15, 4 months 20 days ago

    RedHill Biopharma étudie l'opaganib pour le traitement du virus Ebola en pleine épidémie.

    Essais Cliniques Maladies Infectieuses Opaganib RedHill Biopharma Virus Ebola
  • PRESS RELEASE

    published on 06/03/2026 at 18:10, 4 months 20 days ago

    RedHill Biopharma Advancing Opaganib Options For Ebola Virus Disease Outbreak

    RedHill Biopharma is exploring collaboration opportunities to advance opaganib for Ebola virus disease outbreak, with potential host-directed therapeutic benefits and dual mechanism of action
    Collaboration Clinical Advancement Opaganib RedHill Biopharma Ebola Virus Disease
    Logo of RedHill Biopharma Ltd.
Accesswire
  • Published on 10/24/2026 at 00:25, 13 hours 27 minutes ago

    Caldwell Announces Sale of IQTalent

  • Published on 10/24/2026 at 00:04, 13 hours 48 minutes ago

    Sparta Capital Ltd. Provides Corporate Update on Reinstatement Review, Financial Statement Corrections and Governance Matters

  • Published on 10/23/2026 at 23:30, 14 hours 22 minutes ago

    Algo Grande Commissions Independent NI 43-101 Update to Capture First Year of Progress at Adelita

  • Published on 10/23/2026 at 21:55, 15 hours 57 minutes ago

    Apex Closes Offering and Completes NASDAQ Listing

  • Published on 10/23/2026 at 16:00, 21 hours 52 minutes ago

    Leggett Dynamics's Mid-Class Massage System Wins Gasgoo's Best Technical Practice Award

View all ACCESSWIRE
EQS Group
  • Published on 10/24/2026 at 06:30, 7 hours 22 minutes ago

    AI and EV Boom Draws $690 Million in Advanced Materials Investment Plans to Thailand

  • Published on 10/23/2026 at 18:55, 18 hours 57 minutes ago

    Qatar's Years of Culture Initiative Announces Partner Countries Through 2030

  • Published on 10/23/2026 at 18:00, 19 hours 52 minutes ago

    BIOSYNEX SA: CHEMBIO DIAGNOSTIC SYSTEMS AWARDED $5.7 MILLION TO ADVANCE DPP® BIOTHREAT PANEL

  • Published on 10/23/2026 at 18:00, 19 hours 52 minutes ago

    ABIVAX: Nombre d’actions composant le capital social et nombre total de droits de vote au 30.09.26

  • Published on 10/23/2026 at 17:55, 19 hours 57 minutes ago

    Tout entendre, sans rien téléverser : VoxNexus lance la première intelligence artificielle (IA) vocale pour Android à écoute continue, à faible consommation et entièrement embarquée

View all EQS
Les Echos
  • Published on 10/23/2026 at 20:33, 17 hours 19 minutes ago

    Déclaration hebdomadaire d'opérations effectuées du 19 au 23 octobre 2026

  • Published on 10/23/2026 at 20:33, 17 hours 19 minutes ago

    Disclosure of transactions in own shares from October 19 to October 23, 2026

  • Published on 10/23/2026 at 17:45, 20 hours 7 minutes ago

    Imerys-10-2026-communique-capital-droits-de-vote-au-30-septembre-2026

  • Published on 10/23/2026 at 17:45, 20 hours 7 minutes ago

    Imerys-10-2026-information-share-capital-and-voting-rights-as-of-30-September-2026

  • Published on 10/23/2026 at 17:45, 20 hours 7 minutes ago

    Klarsen : Comptes semestriels 2026

View all LES ECHOS COMFI WIRE

With webdisclosure.com, you can follow all the latest financial news in real time from the best sources for companies listed on the Paris, Brussels, Amsterdam, Lisbon, Frankfurt and New York stock exchanges. You'll have access to summary articles written by us and press releases published by the companies themselves.

©Dissemination technology Webdisclosure.com - copyright 2026 SYMEX ECONOMICS all rights reserved

WebDisclosure

87, rue Ordener - 75018 Paris

Contact us

+33 1 42 23 83 61

Contact Authors Cookies policy Terms and conditions Privacy policy